Maury Raycroft
Stock Analyst at Jefferies
(1.01)
# 3,978
Out of 5,054 analysts
54
Total ratings
29.27%
Success rate
-11.24%
Average return
Main Sectors:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals | Upgrades: Buy | $10 → $21 | $15.68 | +33.93% | 1 | Nov 7, 2025 | |
| OPK OPKO Health | Downgrades: Hold | $2 → $1.6 | $1.33 | +20.30% | 1 | Oct 31, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $550 → $549 | $451.95 | +21.47% | 4 | Oct 30, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Hold | $18 → $7 | $6.18 | +13.27% | 2 | Oct 17, 2025 | |
| KOD Kodiak Sciences | Initiates: Buy | $15 | $19.63 | -23.59% | 1 | Sep 22, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $2.29 | +52.84% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $10.42 | +408.64% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $4.63 | +72.79% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.50 | +497.25% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $1.87 | +274.33% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.36 | +154.24% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $8.38 | +126.73% | 1 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $15 | $3.92 | +282.65% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $39 | $36.10 | +8.03% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.68 | +778.48% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $2.20 | +945.45% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $9.62 | +1,927.03% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $7.23 | +52.14% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $29.71 | -79.80% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $41.50 | +80.72% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $10.04 | +9.56% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $15.14 | +78.34% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $2.20 | +127.27% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $79.17 | -39.37% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $8.89 | +304.95% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $4.53 | +2,217.88% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $55.21 | +211.54% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $4.62 | +917.32% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $10.18 | +312.57% | 3 | Nov 1, 2017 |
Aurinia Pharmaceuticals
Nov 7, 2025
Upgrades: Buy
Price Target: $10 → $21
Current: $15.68
Upside: +33.93%
OPKO Health
Oct 31, 2025
Downgrades: Hold
Price Target: $2 → $1.6
Current: $1.33
Upside: +20.30%
Alnylam Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $550 → $549
Current: $451.95
Upside: +21.47%
Kezar Life Sciences
Oct 17, 2025
Downgrades: Hold
Price Target: $18 → $7
Current: $6.18
Upside: +13.27%
Kodiak Sciences
Sep 22, 2025
Initiates: Buy
Price Target: $15
Current: $19.63
Upside: -23.59%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $2.29
Upside: +52.84%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $10.42
Upside: +408.64%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $4.63
Upside: +72.79%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.50
Upside: +497.25%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $1.87
Upside: +274.33%
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $2.36
Upside: +154.24%
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $8.38
Upside: +126.73%
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $3.92
Upside: +282.65%
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $36.10
Upside: +8.03%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.68
Upside: +778.48%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $2.20
Upside: +945.45%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $9.62
Upside: +1,927.03%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.23
Upside: +52.14%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $29.71
Upside: -79.80%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $41.50
Upside: +80.72%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $10.04
Upside: +9.56%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $15.14
Upside: +78.34%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $2.20
Upside: +127.27%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $79.17
Upside: -39.37%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $8.89
Upside: +304.95%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $4.53
Upside: +2,217.88%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $55.21
Upside: +211.54%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $4.62
Upside: +917.32%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $10.18
Upside: +312.57%